

## Monthly Investment Update March 2024

### **Investment Objective**

Provide a concentrated portfolio of long-only positions in 25-35 Australian and global securities based on the highest conviction ideas from respected fund managers. The Company forgoes any investment fees and instead donates to leading Australian medical research institutes.

### **Portfolio Commentary**

Markets continued their rally into March as the Federal Reserve decided to keep interest rates unchanged despite persistent inflation. The rally continued to broaden with all S&P 500 sectors, except real estate, recording gains in the quarter to March. For the month of March, the S&P 500 increased 3.1%, the Nasdaq increased 1.8%, the ASX 200 was up 2.6%. and the MSCI World Index was up 2.6% in March. The HM1 portfolio continued to perform in March up 1.2% and is up 18% over the past 6 months. The recently announced fully franked dividend of 7 cents per share is payable on 18 April 2024. Since inception in November 2018, the HM1 portfolio has delivered an annualised pre-tax investment return of 10.1% pa and has paid fully franked dividends totalling 53 cents per share.

During March we took the opportunity to speak with Dan Loeb of Third Point about his 2023 Sohn Hearts & Minds Conference stock pick, Bath and Bodyworks (BBWI). The stock has performed very well (+57% since our purchase) and after the discussion, we decided to lock in this outperformance and sell out of the position. Given that it is still early in the Conference Portfolio's 1 year holding period, we have reallocated the funds to Dan's new idea, International Flavours and Fragrances (IFF). This business is a supplier of flavour and fragrance ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. Since our purchase, the company has announced the sale of its Pharma solutions business for close to \$3bn which will reduce its debt by a third. Dan is impressed by the new management team and expects further catalysts to play out this year.

In this month's update, we spoke to TDM Growth Partners for an update on one of their stock picks, Block, Inc. (SQ). Block's recently announced quarterly results outperformed expectations with a 22% year-over-year growth in gross profit. The company also provided FY24 guidance with growth expectations of over 15%. Significant corporate actions, including a 1,000-person reduction in headcount and a corporate reorganisation, underscored a shift towards efficiency and a more focused growth strategy, especially around transforming Cash App into a "social bank." Their results and actions reflect a significant change in management's strategy, with the share price responding positively, up 18% since the announcement. Despite challenges, the company's commitment to margin improvement and operational excellence suggests a positive outlook, with the potential for re-rating in line with other tech companies that have undergone similar efficiency drives. Read further insights from TDM Growth Partners here.

Pre-Tax NTA	\$3.15
Post-Tax NTA	\$3.09
Share Price (ASX: HM1)	\$2.63
Investment Performance p.a. (Since inception 14 Nov 2018)	10.1%
Latest Dividend (Interim dividend payable 18 April 2024)	7cps
Fully Franked Dividend Yield¹	5.3%
Cash Weighting	8%
Profits Reserve (At 31 December 2023)	49cps
Available Franking Credits <sup>2</sup> (At 31 December 2023)	56cps
Cumulative Medical Research Funding	\$48.9m



## **Monthly Investment Update** March 2024

### **HM1 Investment Performance**

Investment Performance	1 month	6 months	1 year	3 years	Since Inception
	111011111	o months	ı yeai	per annum	per annum
HM1 Investment Performance	1.2%	18.3%	14.2%	-1.5%	10.1%
MSCI World Index (AUD)	2.6%	19.0%	26.5%	12.6%	12.5%

HM1 Investment Performance is calculated after expenses and before taxes. The comparator is the MSCI World price index in AUD. Source: Citco Fund Services and www.msci.com. Inception 14 Nov 2018.

### Dividend History

Dividend History	FY21	FY22	FY23	FY24
Dividends – fully franked	12cps	13.5cps	13.5cps	14.0cps

### **Top 10 Core Portfolio Holdings**

Represents 45% of total portfolio holdings (in alphabetical order)



ICE.NYSE





Microsoft Corporation

MSFT.NAS



Rokt





### **Conference Portfolio Holdings**

Represents 28% of total portfolio holdings (in alphabetical order)









ASH.NYSE

NexGen NexGen Energy

WebsterBank<sup>a</sup>

NXG.ASX

Webster Bank WBS.NYSE

Games Workshop GAW.LON

ResMed ResMed

RMD.ASX 7WISE

WISE LON

International Flavours & Fragrances Inc. IFF.NYSE

SWIRE PACIFIC Swire Pacific 0019.HKG



Lamb Weston LW.NYSE



**Telix Pharmaceuticals** TLX.ASX



# Monthly Investment Update March 2024

### News from the HM1 Network



**Block, Inc. (NYSE: SQ)** recently announced quarterly results outperformed expectations with a 22% year-over-year growth in gross profit. The company also provided FY24 guidance with growth expectations of over 15%. Significant corporate actions, including a 1,000-person reduction in headcount and a corporate reorganisation, underscored a shift towards efficiency and a more focused growth strategy, especially around transforming Cash App into a "social bank." Their results and actions reflect a significant change in management's strategy, with the share price responding positively, up 18% since the announcement.



Core Fund Manager, Regal Partners hosted a webinar with Co-Founder & Chief Investment Officer Phil King alongside senior members of Regal's investment team, Jessica Farr-Jones and Gavin George to present their insights on the current investing environment and where Regal Partners is finding opportunities across its diverse range of Australian-focused alternative investment strategies. You can watch the recording here. (Please note, you will need to register to access).



During March, we spoke to Dan Loeb of Third Point about his 2023 Conference stock pick, **Bath and Bodyworks (BBWI).** The stock performed very well (+57% since our purchase) and after the discussion, we decided to lock in this outperformance and sell out of the position. Given it's still early in the Conference Portfolio's 1 year holding period, we have reallocated the funds to Dan's new idea, **International Flavours and Fragrances (IFF).** This business is a supplier of flavour and fragrance ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. Dan is impressed by the new management team and expects further catalysts to play out this year. Other 2023 Conference stock picks for reference can be found here.



**Professor Dan Lubman, Clinical Director of Turning Point,** Australia's leading national addiction treatment, training and research centre. Prof Dan Lubman explains some of the realities of addiction and how change is possible. The video also includes real stories from Craig and Carolyn, two incredible individuals who have lived experiences of addiction and are now making a change and helping other people rethink addiction. <u>You can watch the video here.</u> We're proud to support Turning Point on their research, in partnership with Core Fund Manager Cooper Investors. Their work has helped to transform lives, with more than 100,000 Australians seeking support from clinicians every year.



Discover **Nick Griffin's** formula for double-digit returns, plus 13 stocks Munro Partners (Core & Conference Fund Manager) is backing for the long-term including Kieran Moore's stock pick Wise which Munro Partners <u>pitched at the 2023 Sohn Hearts & Minds Conference.</u> Nick highlights that with interest rates set to come down and AI shaping the future of everything, growth stocks are sure to rally. While growth might be back, sorting the winners from the losers will be the key to driving returns. <u>You can watch Nick's full interview with Livewire here.</u>



Chronic pain is a major and increasing public health issue and affects one in five people in Australia with more than 68% of people of working age living with chronic pain. Chronic pain reduces the quality of life and can cause disability and mental health problems. **The Pain Management Research Institute** has been leading the way in the science and treatment of pain since 1990, and with vital funding, created the patient care priorities framework (Listen to me, Learn from me) to help shape interdisciplinary digital pain education. Read more about the project we are excited to support, in partnership with TDM Growth Partners, here.

Disclaimer: This communication has been prepared by Hearts and Minds Investments Limited (ABN 61 628 753 220) and may contain general information relating to HM1 securities. The general information should not be considered financial advice. HM1 is not licensed to provide financial product advice. The information does not consider the investment objectives, financial situation, or particular needs of any individual. The information is current as at the date of preparation and is subject to change. HM1 does not guarantee repayment of capital or any rate of return on HM1 securities. An investment may achieve a lower-than-expected return and investors risk losing some, or all, of their principal investment. Past performance is not a reliable indicator of future performance. This document may not be reproduced or copies circulated without prior authority from Hearts and Minds Investments Limited.



# Monthly Investment Update March 2024

### **Core Fund Managers**















#### **Conference Fund Managers**









**Ellerston Capital** 







METRONOME CAPITAL LLP



TERRACAPITAL





### **Designated Beneficiaries**





































### **Pro-Bono Service Providers**















Disclaimer: This communication has been prepared by Hearts and Minds Investments Limited (ABN 61 628 753 220) and may contain general information relating to HM1 securities. The general information should not be considered financial advice. HM1 is not licensed to provide financial product advice. The information does not consider the investment objectives, financial situation, or particular needs of any individual. The information is current as at the date of preparation and is subject to change. HM1 does not guarantee repayment of capital or any rate of return on HM1 securities. An investment may achieve a lower-than-expected return and investors risk losing some, or all, of their principal investment. Past performance is not a reliable indicator of future performance. This document may not be reproduced or copies circulated without prior authority from Hearts and Minds Investments Limited.